Abstract: The invention relates to audio transducers, such as loudspeaker, microphones and the like, and includes improvements in or relating to: audio transducer diaphragm structures and assemblies, audio transducer mounting systems; audio transducer diaphragm suspension systems, personal audio devices incorporating the same and any combination thereof. The embodiments of the invention include linear action and rotational action transducers. For both types of transducer, rigid and composite diaphragm constructions and unsupported diaphragm periphery designs are described. Systems and methods for mounting the transducer to a housing, such as an enclosure or baffle are also described. Furthermore, hinge systems including: rigid contact hinge systems and flexible hinge systems are also disclosed for various rotational action transducer embodiments.

Abstract: There is a method and a corresponding system for performing partial write operations to memory. This method and corresponding system utilizes an XOR operation to generate error checking bits. Once the error checking bits are generated, they are then used for error checking a set of data bits so that these data bits can be written to memory.

Abstract: Concepts for partial write operations to memory are presented. Such concepts employ an XOR operation to generate error checking bits that are then used for error checking of data bits for writing to the memory.

Abstract: A monitoring device operable to provide information on data obtained from sensors operably connected between a patient and the device is provided that includes a central processing unit configured to receive incoming data signals from sensors concerning physiological parameters of the patient to compare the incoming data signals to predetermined alarm limits for the physiological parameters to determine an alarm condition and an analytics engine operably connected to the central processing unit and selectively operable to provide predictions of adverse events using the incoming data signals. The central processing unit is configured to alter the alarm limits for at least one of the physiological parameters in response to the activation of the analytics engine to reduce clinically irrelevant alarms.

Abstract: A method of adjusting event detection and alarm generation sensitivity settings of a patient monitoring system includes receiving physiological information from a patient, determining an acuity level of the patient in dependence upon the physiological information received, and at least one of automatically updating a sensitivity setting for a system action in dependence upon the determined acuity level of the patient or prompting a user to manually update the sensitivity setting for the system action in dependence upon the determined acuity level.

Abstract: A monitoring device operable to provide information on data obtained from sensors operably connected between a patient and the device is provided that includes a central processing unit configured to receive incoming data signals from sensors concerning physiological parameters of the patient to compare the incoming data signals to predetermined alarm limits for the physiological parameters to determine an alarm condition and an analytics engine operably connected to the central processing unit and selectively operable to provide predictions of adverse events using the incoming data signals. The central processing unit is configured to alter the alarm limits for at least one of the physiological parameters in response to the activation of the analytics engine to reduce clinically irrelevant alarms.

Abstract: A method of adjusting event detection and alarm generation sensitivity settings of a patient monitoring system includes receiving physiological information from a patient, determining an acuity level of the patient in dependence upon the physiological information received, and at least one of automatically updating a sensitivity setting for a system action in dependence upon the determined acuity level of the patient or prompting a user to manually update the sensitivity setting for the system action in dependence upon the determined acuity level.

Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

Abstract: This invention relates to compounds of formula (I)

Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.

Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

Abstract: The use of a compound comprising formula (I): or a salt, ester, amide or prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

Abstract: This invention relates to compounds of formula (I)

Abstract: This invention relates to compounds of formula (I)

Abstract: This invention relates to compounds of formula (I).

Abstract: An apparatus, system, and method are disclosed for mandatory end to end integrity checking. The apparatus includes a compatibility module configured to monitor data from a source and verify integrity information compatibility with a standard, and an integrity module configured to wrap the data from the source with additional integrity information. The system includes a source configured to send data over a network, a target configured to receive data over the network, the apparatus, a main memory module, a storage controller, and a storage device. The method includes monitoring data from a source, verifying integrity information compatibility with a standard, and wrapping the data from the source with additional integrity information.

Abstract: The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR2, R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R2 is hydrogen or a group as defined for R1.

Abstract: This invention relates to compounds of formula (I).